Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 3
---
 issued and outstanding.

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2025

TABLE OF CONTENTS</div>

|                                |                                                                                                                                                                                                                                                                                                   | Page |
| PART 1 - FINANCIAL INFORMATION |                                                                                                                                                                                                                                                                                                   |    1 |
| Item 1.                        | Financial Statements (Unaudited)                                                                                                                                                                                                                                                                  |    1 |
|                                | Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024                                                                                                                                                                                                              |    1 |
|                                | Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 (Successor), the Three Months Ended September 30, 2024, Period from February 14, 2024 through September 30, 2024 (Successor), and January 1, 2024 through February 13, 2024 (Predecessor)  |    2 |
|                                | Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the Three and Nine Months ended September 30, 2025 (Successor), Periods from February 14, 2024 through September 30, 2024 (Successor), and January 1, 2024 through February 13, 2024 (Predecessor) |    3 |
|                                | Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 (Successor), Period from February 14, 2024 through September 30, 2024 (Successor), and January 1, 2024 through February 13, 2024 (Predecessor)                                                       |    5 |
|                                | Notes to Condensed Consolidated Financial Statements (Unaudited)                                                                                                                                                                                                                                  |    6 |
| Item 2.                        | Management’s Discussion and Analysis of Financial Condition and Results of Operations                                                                                                                                                                                                             |   34 |
| Item 3.                        | Quantitative and Qualitative Disclosures about Market Risk                                                                                                                                                                                                                                        |   44 |
| Item 4.                        | Controls and Procedures                                                                                                                                                                                                                                                                           |   44 |
| PART II - OTHER INFORMATION    |                                                                                                                                                                                                                                                                                                   |   45 |
| Item 1.                        | Legal Proceedings                                                                                                                                                                                                                                                                                 |   45 |
| Item 1A